Braidwell’s Nurix Therapeutics NRIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$20.7M Sell
871,104
-415,665
-32% -$10.4M 0.86% 51
2026
Q2
$31.2M Sell
1,286,769
-463,997
-27% -$7.9M 1.15% 34
2026
Q1
$27.1M Sell
1,750,766
-433,098
-20% -$7.18M 0.91% 42
2025
Q4
$41.4M Buy
+2,183,864
New +$31.4M 1.32% 30

Other funds holding NRIX

Braidwell's NRIX Position: Q3 2026 in Review

Braidwell reduced its Nurix Therapeutics (NRIX) stake by 32% in Q3 2026, selling an estimated $10.4M and leaving 871,104 shares worth $20.7M. The position accounts for 0.86% of the portfolio, ranked #51.

Braidwell first reported a position in NRIX in Q4 2025 and has held it in 4 quarters since. The position peaked at $41.4M in Q4 2025. 233 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.

  • Braidwell held 871,104 shares of Nurix Therapeutics worth $20.7M as of Q3 2026.
  • Braidwell sold 415,665 Nurix Therapeutics shares in Q3 2026, an estimated $10.4M.
  • Nurix Therapeutics made up 0.86% of Braidwell's portfolio in Q3 2026, its #51 holding.
  • Braidwell first reported a position in Nurix Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Braidwell's Nurix Therapeutics position peaked at $41.4M in Q4 2025.
  • 233 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.

Based on Braidwell's 13F filing for Q3 2026, filed 16 Nov 2026.